Evidence map›Paper›PMID 37961729›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA.

Ludy R Carmola, Allison Dorothy Roebling, Dara Khosravi, Rose M Langsjoen, Andrei Bombin, Bri Bixler, Alex Reid, Cara Chen, Ethan Wang, Yang Lu and 18 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 2 institutions in 1 country.

Ludy R CarmolaDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Allison Dorothy RoeblingGeorgia Emerging Infections Program; Georgia Department of Health; Atlanta, GA, 30303; USA.
Dara KhosraviDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Rose M LangsjoenDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Andrei BombinDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.ORCID 0000-0003-2445-304X
Bri BixlerGraduate Program in Genetics and Molecular Biology, Emory University; Atlanta, GA, 30322; USA.
Alex ReidDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Cara ChenDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Ethan WangDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Yang LuDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Ziduo ZhengDepartment of Biostatistics and Bioinformatics; Rollins School of Public Health, Emory University; Atlanta, GA, 30322; USA.
Rebecca ZhangDepartment of Biostatistics and Bioinformatics; Rollins School of Public Health, Emory University; Atlanta, GA, 30322; USA.
Phuong-Vi NguyenDivision of Infectious Diseases; Department of Medicine, Emory University School of Medicine; Atlanta, GA, 30322; USA.
Robert A ArthurEmory Integrated Computational Core; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Eric FittsDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Dalia Arafat GulickGeorgia Clinical & Translational Science Alliance; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Dustin HigginbothamGeorgia Clinical & Translational Science Alliance; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Azmain TazDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Alaa AhmedDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
John Hunter CrumplerDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.ORCID 0009-0006-5970-5170
Colleen KraftDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Wilbur A LamThe Atlanta Center for Microsystems-Engineered Point-of-Care Technologies; Atlanta, GA, 30322; USA.
Ahmed BabikerDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.ORCID 0000-0003-0578-4871
Jesse J WaggonerDivision of Infectious Diseases; Department of Medicine, Emory University School of Medicine; Atlanta, GA, 30322; USA.
Kyle P OpenoGeorgia Emerging Infections Program; Georgia Department of Health; Atlanta, GA, 30303; USA.
Laura M JohnsonPediatric Biostatistics Core; Department of Pediatrics; School of Medicine; Emory University; Atlanta, GA, 30322; USA.
Adrianna WestbrookPediatric Biostatistics Core; Department of Pediatrics; School of Medicine; Emory University; Atlanta, GA, 30322; USA.
Anne PiantadosiDepartment of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA, 30322; USA.
Emory University · USGeorgia Institute of Technology · US

Funding

Technology Training and Dissemination CoreU54EB027690 · NIBIB · EMORY UNIVERSITY · PI Wilbur A Lam · 2018 to 2026
$96.1M
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Training a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4M
ACL HHS U54CK000485NCATS NIH HHS UL1 TR002378NCEZID CDC HHS U54 CK000485NIAID NIH HHS T32 AI074492NIBIB NIH HHS U54 EB027690
6 · The paper itself

Abstract

While SARS-CoV-2 vaccines have shown strong efficacy, their suboptimal uptake combined with the continued emergence of new viral variants raises concerns about the ongoing and future public health impact of COVID-19. We investigated viral and host factors, including vaccination status, that were associated with SARS-CoV-2 disease severity in a setting with low vaccination rates. We analyzed clinical and demographic data from 1,957 individuals in the state of Georgia, USA, coupled with viral genome sequencing from 1,185 samples. We found no difference in disease severity between individuals infected with Delta and Omicron variants among the participants in this study, after controlling for other factors, and we found no specific mutations associated with disease severity. Compared to those who were unvaccinated, vaccinated individuals experienced less severe SARS-CoV-2 disease, and the effect was similar for both variants. Vaccination within 270 days before infection was associated with decreased odds of moderate and severe outcomes, with the strongest association observed at 91-270 days post-vaccination. Older age and underlying health conditions, especially immunosuppression and renal disease, were associated with increased disease severity. Overall, this study provides insights into the impact of vaccination status, variants/mutations, and clinical factors on disease severity in SARS-CoV-2 infection when vaccination rates are low. Understanding these associations will help refine and reinforce messaging around the crucial importance of vaccination in mitigating the severity of SARS-CoV-2 disease.

Indexed as

disease severitypost-vaccine infectionSARS-CoV-2

Identifiers

PMID37961729
PMCPMC10635197
OpenAlexW4387933045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.